Pfizer's biosimilar of Amgen, J & J's anemia treatments gets FDA nod

(Reuters) - Pfizer Inc's Retacrit was approved by U.S. health regulators as a biosimilar to current anemia treatments from Amgen Inc and Johnson& Johnson on Tuesday, setting it up to compete against more established brands.

Source: Reuters: Health - May 15, 2018 Category: Consumer Health News Tags: healthNews Source Type: news